Sotera Health (SHC) Stock: Buy, Sell, or Hold?
SHC - Sotera Health Company Common Stock
$18.13
0.36 (2.03%)
▲
5d:
+0.33%
30d:
-0.87%
90d:
+4.5%
BUY
HIGH Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 03, 2026
10d
Get Alerted When SHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SHC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: SHC shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.45
Based on 6.7% avg growth
INTRINSIC VALUE TODAY
$15.18
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SHC is currently trading at $18.13, which is considered fair relative to its 30-day fair value range of $17.91 to $18.71. The stock's valuation (Forward PE: 16.9) is in line with its historical norms (16.5). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $18.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.61 (+24.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SHC is in a strong uptrend. The price is approaching resistance at $18.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SHC scores 76/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $22.61 (+24.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$17.91 -
$18.71
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (76/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.7% below Wall St target ($22.61)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
- BULLISH: Bottoming setup score 76/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$17.91 -
$18.71
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$17.51
Resistance Level
$18.52
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
16.87
Wall Street Target
$22.61
(+24.7%)
Revenue Growth (YoY)
9.2%
Earnings Growth (YoY)
569.5%
Profit Margin
13.4%
Valuation Premium vs History
+0.7% premium
PE vs Historical
16.9 vs 16.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$18.26
(+1%)
2-Year Target
$18.38
(+1%)
3-Year Target
$18.51
(+2%)
3-Yr Target (if PE normalizes)
(PE: 17→17)
PE COMPRESSION
$18.11
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 9.3%)
$27.85
(+54%)
Base:
(SPY PE: 16.9, Growth: 9.3%)
$23.65
(+31%)
Bear:
(PE: 14.3, Growth: 9.3%)
$20.11
(+11%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (31x PE), but valuation improves significantly next year (17x PE) as earnings recover.
Trailing PE: 31.18 | Current EPS (TTM): $0.57
Bull Case
$36.86
(+103%)
Analyst growth 88.6%, PE expands to 34.3
Base Case
$33.51
(+85%)
Market implied 88.6%, PE stable at 31.2
Bear Case
$12.08
(-33%)
Severe decline -20.0%, PE contracts to 26.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 22, 2026 11:03 PM ET
Data refreshes hourly during market hours. Next update: 12:03 AM
Data refreshes hourly during market hours. Next update: 12:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
GH
Guardant Health Inc |
STRONG BUY
26 analysts |
$202 | 67 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
28 analysts |
$691 | 41 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
23 analysts |
$404 | 59 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$244 | 36 SELL |
